Biomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
Vienna, November 13, 2023
Biomay expanded its biomanufacturing facility in central Vienna, 9th district, by adding clean rooms, laboratories, and warehouse premises in the Vienna Competence Center building. Besides the 4000 sqm main site in Vienna 22nd district, Biomay now operates an additional 2000 sqm integrated biomanufacturing facility, equipped with five GMP-commissioned clean rooms for upstream and downstream processing and aseptic filling. Furthermore, the site features comprehensive laboratories for quality control, process and assay development.
A New Center of Excellence for mRNA
The upgraded site will serve as Biomay's Center of Excellence for end-to-end Contract Development and Manufacturing Organization (CDMO) services, specifically for messenger RNA (mRNA) manufacturing. The GMP service offerings for mRNA include plasmid cell banking, circular plasmid and linear DNA template manufacturing, in-vitro transcription (IVT) of mRNA drug substance, and aseptic filling of mRNA drug product. Biomay employs cutting-edge enzymatic run-off transcription based on linear DNA templates for mRNA processing, offering various options for 5´-capping, 3´-poly-adenylation, and nucleotide modification as per client requirements.
Notably, Biomay has a strong track record in GMP production of linear DNA templates, supplying significant amounts of these templates during the COVID-19 pandemic for the manufacturing of a COVID-19 mRNA vaccine. The company has also gained extensive experience in GMP manufacturing of DNA templates for other clinical indications, such as oncology.
Aseptic Filling Capacities
Biomay's aseptic filling capacities include a seven-glove isolator equipped with an automated processing line for aseptic filling, vial capping and crimping, primarily serving clinical-stage investigational medicinal products (IMPs). Dr. Angela Neubauer, the Site Head of the facility and Biomay's Senior Vice President Client Business, emphasized the company's evolution from being a drug substance and API manufacturer to offering drug product aseptic filling, testing and release services. She highlighted Biomay's strategic goal of establishing itself as a leading player in the mRNA CDMO field, alongside its existing expertise in proteins and plasmids.
Contacts
Dr. Angela NeubauerSVP Client BusinessBiomay AG
Ada Lovelace-Str. 2
A-1220 Vienna, Austria
Images
Links
About Biomay
Founded in 1984, Biomay AG is a fully integrated CDMO with a focus on microbial based GMP services for manufacturing therapeutic proteins, plasmid DNA and mRNA. The new site complements Biomay’s main manufacturing site in Vienna Seestadt (22nd district, Ada Lovelace-Strasse), established in 2021.
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
x-cardiac GmbH: Successful MDR Certification for AI Solution in Predicting Postoperative Complications – New Product Generation for Optimized Patient Safety2.10.2024 06:00:00 CEST | Press release
Berlin, October 2, 2024 x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform. This certification introduces a completely new generation of products offering state-of-the-art technologies to optimize patient care and safety.
German Federal Chancellor Scholz, WHO Director-General Dr Tedros and Bill Gates at the World Health Summit 20241.10.2024 09:55:00 CEST | Press release
The world's leading global health conference begins on October 13.
Taicang Day celebrates deepening China-Germany cooperation1.10.2024 08:31:23 CEST | Press release
Hamburg, Germany - The Taicang Day event was held Thursday in the northern German city of Hamburg, with participants highlighting the broad prospects for continued win-win cooperation between China and Germany.
Bertelsmann Stiftung: Where leading countries stand in the transition to renewable heating, road transport and electricity1.10.2024 08:00:00 CEST | Press release
The sluggish rate of progress made in the energy transition is putting the goal of reducing greenhouse gas emissions to zero by the middle of the century at risk. A comparison of four European countries shows that Denmark and Norway are making significant strides in transitioning to renewable heating and electricity. Norway is also advancing quickly in the road transport sector. The UK and Germany continue to face several challenges.
Better performance and scalability for Adobe AEM users: Cognizant Netcentric launches the revolutionary EDS+ solution30.9.2024 16:00:00 CEST | Press release
Perfect page performance and SEO scores, simplified content integration, AI support and significant cost reductions set EDS+ apart
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom